To the full analysis
Ginkgo Bioworks Holdings stock: growth
DNAGinkgo Bioworks Holdings reported $170.16M in revenue for fiscal 2025, down 25.1% on the prior year, up 17.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
21%
per year from 2019 to 2025, per share 8.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 17.3% | 21.0% |
| Revenue per share | 4.8% | 8.4% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $54.18M | −$119.33M | −$66.88M |
| 2020 | $76.66M | −$126.61M | −$193.65M |
| 2021 | $313.84M | −$1.83B | −$310.34M |
| 2022 | $477.71M | −$2.1B | −$304.47M |
| 2023 | $251.46M | −$892.87M | −$336.3M |
| 2024 | $227.04M | −$547.03M | −$382.13M |
| 2025 | $170.16M | −$312.76M | −$178.72M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.